Martin Ashley M, Tribuzi Andrea, Schieber Maggie L, Reiter Pamela D
Department of Pharmacy (AMM, AT, PDR), Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO.
Skaggs School of Pharmacy and Pharmaceutical Sciences (MLS, PDR), University of Colorado, Anschutz Medical Campus, Aurora, CO.
J Pediatr Pharmacol Ther. 2022;27(3):263-269. doi: 10.5863/1551-6776-27.3.263. Epub 2022 Mar 21.
To evaluate adherence to an institutional continuous infusion propofol policy for sedation in mechanically ventilated patients, investigate the rate of propofol-related infusion syndrome (PRIS), and explore areas of improvement to enhance policy compliance and safety.
This was a single center, retrospective chart review of patients admitted to a pediatric or cardiac intensive care unit within a large free-standing quaternary care pediatric hospital who received continuous propofol for non-procedural continuous sedation for at least 6 hours between 2014 and 2019. Propofol exposure (dose and duration), laboratory data, and hemodynamic outcomes of patients were evaluated.
A total of 104 patients (108 admissions and 133 treatment courses) met inclusion criteria. Policy adherence to propofol dosing and duration limitations were 70% (93/133 courses) and 68% (91/133 courses), respectively. Adherence to all elements of laboratory and hemodynamic monitoring was 23%. Hypotension and bradycardia were common among patients during propofol treatment courses. Except for hypertriglyceridemia, no significant difference in specific laboratory values were detected between patients exposed to greater than 66 mcg/kg/min (4 mg/kg/hr), compared with those exposed to less than 66 mcg/kg/min of propofol. Patients receiving therapy for longer than 48 hours had the highest rates of laboratory values associated with PRIS. No patient in the study cohort met full criteria for PRIS.
Adherence to elements of an institutional propofol policy was variable. Improvements in policy adherence may be enhanced by updating policy features, leveraging the electronic medical record order-set, and gaining consensus among key stakeholders.
评估对机构制定的机械通气患者丙泊酚持续输注镇静方案的依从性,调查丙泊酚相关输注综合征(PRIS)的发生率,并探索改进领域以提高方案依从性和安全性。
这是一项单中心回顾性病历审查,研究对象为一家大型独立四级儿科医院的儿科或心脏重症监护病房收治的患者,这些患者在2014年至2019年期间接受丙泊酚进行非手术持续镇静至少6小时。评估了患者的丙泊酚暴露情况(剂量和持续时间)、实验室数据及血流动力学结果。
共有104例患者(108次入院和133个治疗疗程)符合纳入标准。丙泊酚给药和持续时间限制的方案依从性分别为70%(93/133个疗程)和68%(91/133个疗程)。实验室和血流动力学监测所有要素的依从性为23%。在丙泊酚治疗疗程中,患者低血压和心动过缓很常见。除高甘油三酯血症外,丙泊酚暴露量大于66微克/千克/分钟(4毫克/千克/小时)的患者与暴露量小于66微克/千克/分钟的患者相比,特定实验室值无显著差异。接受治疗超过48小时的患者PRIS相关实验室值发生率最高。研究队列中无患者符合PRIS的全部标准。
对机构丙泊酚方案要素的依从性参差不齐。可通过更新方案特点、利用电子病历医嘱集以及在关键利益相关者之间达成共识来提高方案依从性。